Residual vitreous base after vitreoretinal surgery was evaluated by ultrasound biomicroscopy (UBM). Twenty aphakic and pseudoaphakic patients (20 eyes) undergoing surgery for different vitreoretinal diseases were evaluated by high-frequency (50 MHz), high-resolution (50 µm) UBM, performed the day before surgery, weekly up to 1 month after surgery and then monthly. One week after surgery, the vitreous remnants were ‘hardly visible’ in 3 cases, ‘visible’ in 6 cases and ‘highly visible’ in 11. At the end of the follow-up (2.2 months), the ‘hardly visible’ cases increased to 6 and the ‘visible’ cases to 12, while the ‘highly visible’ cases decreased to 2. UBM demonstrated that vitreous base remnants were present in spite of accurate surgery; a spontaneous volume reduction of vitreous was observed during the follow-up.

Keywords:
Ultrasound biomicroscopy, Vitreous base, Vitreoretinal surgery
1.
Michels RC, Wilkinson CP, Rice TA: Retinal Detachment. St Louis, Mosby, 1990, pp 12–97.
2.
Lewis H, Aaberg TM, Abrams GW: Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol 1991;111:8–14.
3.
Aaberg TM: Management of anterior and posterior proliferative vitreoretinopathy. XLV. Edward Jackson Memorial Lecture. Am J Ophthalmol 1988;106:519–532.
4.
Matsuo T, Shiraga F, Matsuo N: Intraoperative observation of the vitreous base in patients with atopic dermatitis and retinal detachment. Retina 1995;15:286–290.
5.
Gentile RC, Berinstein DM, Liebmann J, Rosen R, Stegman Z, Tello C, Walsh JB, Ritch R: High-resolution ultrasound biomicroscopy of the pars plana and peripheral retina. Ophthalmology 1998;105:478–484.
6.
Eguchi S, Araie M: A new ophthalmic electronic videoendoscope system for intraocular surgery. Arch Ophthalmol 1990;108:1778–1781.
7.
Azzolini C, Pierro L, Codenotti M, Bandello F, Brancato R: Ultrasound biomicroscopy following the intraocular use of silicone oil. Int Ophthalmol 1995–1996;19:191–195.
8.
Lopez PF, Grossniklaus HE, Aaberg TM, Sternberg P Jr, Capone A, Lambert HM: Pathogenetic mechanisms in anterior proliferative vitreoretinopathy. Am J Ophthal 1992;114:257–279.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.